BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1699592)

  • 1. Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma.
    Nouri AM; Smith ME; Crosby D; Oliver RT
    Br J Cancer; 1990 Oct; 62(4):603-6. PubMed ID: 1699592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.
    Smith ME; Marsh SG; Bodmer JG; Gelsthorpe K; Bodmer WF
    Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5557-61. PubMed ID: 2473473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
    Cordon-Cardo C; Fuks Z; Drobnjak M; Moreno C; Eisenbach L; Feldman M
    Cancer Res; 1991 Dec; 51(23 Pt 1):6372-80. PubMed ID: 1933900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DR antigen expression and lymphocyte subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections.
    Ioachim-Velogianni E; Stavropoulos NE; Kitsiou E; Stefanaki S; Agnantis NJ
    J Pathol; 1994 Nov; 174(3):183-9. PubMed ID: 7823251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence.
    Möller P; Koretz K; Schlag P; Momburg F
    Int J Cancer Suppl; 1991; 6():155-62. PubMed ID: 1712347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.
    Cromme FV; van Bommel PF; Walboomers JM; Gallee MP; Stern PL; Kenemans P; Helmerhorst TJ; Stukart MJ; Meijer CJ
    Br J Cancer; 1994 Jun; 69(6):1176-81. PubMed ID: 8198988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective expression of adhesion molecules on human bladder tumour and human tumour cell lines.
    Nouri AM; Hussain RF; Dos Santos AV; Oliver RT
    Urol Int; 1996; 56(1):6-12. PubMed ID: 8903546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.
    Möller P; Momburg F; Koretz K; Moldenhauer G; Herfarth C; Otto HF; Hämmerling GJ; Schlag P
    Cancer Res; 1991 Jan; 51(2):729-36. PubMed ID: 1985791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-A, B and DR in Caucasians with transitional cell carcinoma of the bladder.
    Saunders PH; Anderson SA; Stogdill VD; Lamm DL
    Tissue Antigens; 1983 Nov; 22(5):389-92. PubMed ID: 6581580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma.
    Tomita Y; Matsumoto Y; Nishiyama T; Fujiwara M
    J Pathol; 1990 Oct; 162(2):157-64. PubMed ID: 2250194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer.
    Kaklamanis L; Gatter KC; Hill AB; Mortensen N; Harris AL; Krausa P; McMichael A; Bodmer JG; Bodmer WF
    Int J Cancer; 1992 May; 51(3):379-85. PubMed ID: 1592528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines.
    Ottesen SS; Ahrenkiel V; Kieler J
    Cancer Immunol Immunother; 1990; 31(2):93-8. PubMed ID: 2108803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Types of HLA in the bladder transitional cell carcinoma (TCC).
    Yılmaz E; Uğur Özalp A; Cekmen A; Eren B; Onal B; Akkuş E; Erdoğan E
    Med Glas (Zenica); 2013 Feb; 10(1):133-6. PubMed ID: 23348175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-polarized cell surface expression of HLA-A,B,C and HLA-DR antigens in Graves' thyroid follicle cells.
    Mölne J; Nilsson M; Jansson S; Hansson G; Ericson LE
    Autoimmunity; 1991; 10(3):189-99. PubMed ID: 1756224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luminal epithelial antigen (LEA.135) expression correlates with tumor progression for transitional carcinoma of the bladder.
    Jones HL; Delahunt B; Bethwaite PB; Thornton A
    Anticancer Res; 1997; 17(1B):685-7. PubMed ID: 9066602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma.
    Gan LH; Huang LF; Zhang X; Lin A; Xu DP; Wang Q; Wang TJ; Yan WH
    Hum Immunol; 2010 Sep; 71(9):899-904. PubMed ID: 20600448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histocompatibility profile of selected Latin American countries.
    Santiago-Delpín EA
    Transplant Proc; 1991 Apr; 23(2):1861-4. PubMed ID: 2053180
    [No Abstract]   [Full Text] [Related]  

  • 18. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx.
    Esteban F; Concha A; Huelin C; Pérez-Ayala M; Pedrinaci S; Ruiz-Cabello F; Garrido F
    Int J Cancer; 1989 Mar; 43(3):436-42. PubMed ID: 2647639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular localization of blood group antigens (including HLA markers) in human bladder urothelium.
    Gane P; Ruttyn Y; Rouger P; Vallancien G; Salmon C
    Tissue Antigens; 1988 Aug; 32(2):57-70. PubMed ID: 3057680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma.
    Momburg F; Ziegler A; Harpprecht J; Möller P; Moldenhauer G; Hämmerling GJ
    J Immunol; 1989 Jan; 142(1):352-8. PubMed ID: 2462591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.